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Abstract
Background: Panic disorder (PD) patients show more physical and psychological impairment, than the general 
population. Objectives: Our aims are to compare quality of life between PD patients during treatment and healthy 
subjects and to associate social, demographic and clinical factors with quality of life scores. Methods: It is a cross-
sectional study with 20 PD patients and 20 healthy controls. Anxiety levels assessment: Beck Anxiety Inventory, 
Hamilton Anxiety Rating Scale, STAIT − Form Y. Panic severity; Panic Agoraphobia Scale; social and environmental 
problems and global assessment functioning (Axis IV and V, DSM-IV-TR) and quality of life by WHOQOL-BREF. Re-
sults: PD patients were 65% female. Mean age = 37.55 ± 9.06. Quality of life domain scores: physical = 57.86 ± 17.56; 
psychological = 56.04 ± 18.31; social = 56.25 ± 25.92; and environmental = 47.03 ± 16.92; smokers = 20%; BAI = 23.40 
± 15; STAI-S= 43.50 ± 8.79; STAI-T = 50.10 ± 9.19; PAS = 13.60 ± 9.40. Discussion: No significant differences were 
observed between groups about gender, age, schooling, religion, marital status nor individual income, but family 
income was significantly higher among controls. All domains of quality of life are significantly impaired among PD 
patients, compared to healthy controls. Panic disorder compromises well being. Psychosocial problems and high 
levels of anxiety can also negatively impact quality of life of PD patients. 
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Resumo
Contexto: Pacientes com transtorno de pânico (TP) apresentam maior comprometimento físico e psicológico que a 
população geral. Objetivos: Comparar escores de qualidade de vida entre pacientes com TP em tratamento e indiví-
duos normais. Métodos: Trata-se de estudo transversal com 20 portadores de TP e 20 controles normais. Avaliação 
da ansiedade inclui: Inventário de Ansiedade de Beck, Escala de Ansiedade de Hamilton, Inventário de Estado e Traço 
Ansioso, Escala de Pânico e Agorafobia; além de avaliação de problemas sociais e ambientais e funcionamento global 
(eixos IV e V, DSM-IV-TR) e de qualidade de vida pela WHOQOL-BREF. Resultados: Dos pacientes com TP, 65% eram 
do sexo feminino. A média de idade foi de 37,55 ± 9,06 anos. Os escores de qualidade de vida foram: físico = 57,86 ± 
17,56; psicológico = 56,04 ± 18,31; social = 56,25 ± 25,92; e ambiental 47,03 ± 16,92. Tabagistas = 20%. BAI = 23,40 ± 15; 
STAI-S = 43,50 ± 8,79; STAI-T = 50,10 ± 9,19; PAS = 13,60 ± 9,40. Não houve diferenças significativas entre os grupos 
Endereço para correspondência: Valfrido Leão de Melo-Neto. Rua Bulhões Carvalho 473, ap. 1002 – 22081-000 – Copacabana,  Rio de Janeiro, RJ. E-mail: valfrido@gmail.com
50 Melo-Neto, V.L. et al. / Rev. Psiq. Clín 35 (2); 49-54, 2008
Introduction
Panic disorder (PD) is a mental disorder with lifetime 
prevalence rates varying from 1,5%1 to more than 3%2 
of general population. Women are more susceptible 
than men to present this disorder (5% against 2%, 
respectively)3.
Retrospective studies show that more than 80% of PD 
patients correlate stressful life events in the year before 
the PD diagnostic and many of them believe that such 
events contribute to the development of the disorder4,5. 
One population study demonstrated that patients 
with generalized anxiety disorder (GAD), obsessive 
compulsive disorder (ODC) and PD showed the lower 
quality of life scores, among all anxiety disorders6. This 
demonstrates that anxiety disorders must be a priority 
among health care services6. On the other hand, anxiety 
disorders such as PD, worse quality of life in patients 
with medical co-morbidities, as those with chronic 
obstructive pulmonary disease7. The psychological 
suffering provoked by PD is higher than that caused 
by hypertension, diabetes mellitus, arthritis or cardiac 
disease8. Severity of PD is correlated to Quality of Well-
Being Scale9 and Sheehan Disability Scale10. 
Thirty-five percent of the PD patients in general 
population believe that they have bad physical health 
and 38% feel they are emotionally compromised1. In 
fact, PD patients show more physical and psychological 
impairment, than the general population, and than those 
with social anxiety, suggesting that PD is more related 
to worse quality of live than does the social anxiety 
disorder8.
A comparative study between PD patients and he-
althy controls determined that features such as worse 
schooling, greater neuroticism, major depression co-
morbidity, and advanced age are the main factors for 
worsening quality of life evaluated by the SF-3611.
Several authors demonstrate that treatment impro-
ves quality of life among PD patients9,12. On the other 
hand, one study observed that PD patients treated with 
Cognitive Behavioral Therapy, even not presenting 
prominent symptoms of PD nor agoraphobia showed 
lower self development and worse physical health than 
controls, demonstrating that reducing symptoms does 
not mean improvement of the well being and it is neces-
sary more incisive therapeutic modalities13.
The present study aims to compare quality of life 
of PD patients under treatment with a healthy subject 
sample, and also to investigate the association between 
socio-demographic and clinical factors and quality of 
life of PD patients. 
Method
1. Study design and setting
A cross-sectional study of 40 subjects (20 PD patients and 20 
healthy controls) was carried out at the Panic and Respira-
tion Laboratory, in the Institute of Psychiatry of the Federal 
University of Rio de Janeiro (IPUB-UFRJ), Brazil.
2. Participants and assessment
All subjects were interviewed by a psychiatrist using the 
Mini-International Neuropsychiatric Interview version 
4.4 - MINI14, searching for Axis I diagnoses. Twenty 
healthy controls were randomly selected, among the 
list of employers and trainees of a private psychiatric 
hospital of Rio de Janeiro, they did not met criteria for 
any of the Axis I, DSM-IV-TR15 diagnoses researched by 
the MINI and were paired to twenty patients, who were 
under treatment (taking medicine associated or not to 
psychotherapy) at the Panic and Respiration Laboratory 
(IPUB-UFRJ) and met the DSM-IV-TR15 criteria for PD, 
with or without another psychiatric disorder. Six subjects 
could not participate of the “mentally healthy control 
group” since they were diagnosed as sufferers from 
generalized anxiety disorder (n = 4), social phobia (n 
= 2) and or major depressive episode (n = 3) and were 
substituted by another six subjects that were paired to 
the patients. The “new” diagnosed subjects were ins-
tructed to seek for psychiatric treatment at the Federal 
University of Rio de Janeiro. The panic patients already 
were on treatment when they were consecutively asses-
sed and selected to participate of this survey according 
to their returning on the Panic and Respiration Labora-
tory to continue their treatment. It is important to note 
that this sample was composed by patients during their 
treatment, some had mild or residual symptoms, others 
em relação a sexo, idade, escolaridade, religião, estado civil, nem renda individual, porém a renda familiar do grupo-
controle foi significativamente maior. Todos os domínios de qualidade de vida foram bem piores entre os pacientes 
com TP em tratamento, quando comparados aos controles. Conclusões: TP, mesmo em tratamento, compromete a 
qualidade de vida. Problemas psicossociais e altos níveis de ansiedade podem ter impacto negativo na qualidade de 
vida dos pacientes com TP. 
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had no panic disorder symptoms. They had anxiety as-
pects assessed by the Beck Anxiety Inventory – BAI16, 
Hamilton Anxiety Rating Scale - HARS17 and State-Trait 
Anxiety Inventory – Form Y – STAI18 while PD overall se-
verity was evaluated by the Panic and Agoraphobia Scale 
– PAS19. Both groups were investigated by the World 
Health Organization – Quality of Life – brief version – 
WHOQOL-BREF20, to complete the evaluation of quality 
of life in four domains: physical, psychological, social and 
environmental. Demographic data were collected by a 
semi-structured questionnaire created for this survey. 
Patients were also evaluated by the DSM-IV-TR Axis IV 
and V (Environmental and Psychosocial Problems and 
Global Assessment Functioning, respectively). 
The “healthy control group” had the following in-
clusion criteria: 1) to give informed written consent; 
2) to have at least 4 years of schooling; 3) to be pair 
matched in gender and age to a participant of panic 
disorder group. The exclusion criteria were: 1) to meet 
diagnostic criteria of any psychiatric disorder according 
to the MINI evaluation: 2) to have mental retardation. 
Some subjects presented physical illnesses but we did 
not exclude them for that. Twenty per cent had syste-
mic arterial hypertension, 15% had dyslipidemia and 5% 
had diabetes mellitus, but all were employed, active and 
did not have severe limitations in their lives because of 
those physical problems. On the other hand, we also 
did not exclude panic patients with physical problems. 
Although, they referred that physical illnesses were 
under control.
The “panic disorder group” had the following inclu-
sion criteria: 1) to give informed written consent; 2) to 
have at least 4 years of schooling; 3) to be between 18 and 
60 years old; 4) to meet the diagnostic criteria of panic 
disorder according to DSM-IV-TR criteria; 5) to be under 
treatment to panic disorder at the Laboratory of Panic 
and Respiration (IPUB-UFRJ). The exclusion criteria 
were: 1) to have another main psychiatric diagnostic not 
panic disorder; 2) to have mental retardation.
Our local Ethics Committee approved the protocol, 
which complied with the principles of the Declaration of 
Helsinki. All patients gave informed written consent. 
3. Statistical analysis
The HARS (mild anxiety, 18-24; moderate 25-29; severe 
> 29), BAI (minimal or mild anxiety, 0-15; moderate, 16-
25, severe, 26-63), STAI (low anxiety, 20-39; moderate, 
40-59; high, 60-80) scales, and Axis IV (present, not 
present) and Axis V (71-100, good; 51-70, moderate; 
00-50, poor) questionnaires were treated as categorical 
variables, generating absolute and relative frequencies. 
BAI, STAI and PAS were also treated as continuous varia-
bles and had expressed means and standard deviations 
(SD). The four domains of the WHOQOL-BREF, were 
analyzed separately, as continuous variables. Student´s 
t-test was used for the analysis of continuous variables. 
Descriptive analysis established 95% as the confidence 
interval. Chi-square and Kruskal-Wallis test were used 
to compare two groups. The SPSS 12.0 program was 
used to calculate the four quality of life domain scores. 
Epi-Info 6.0 was used to analyze the remaining data. 
Results
The social and demographic data are described at table 1. 
No significant differences were observed between groups 
about gender, age, schooling, religion, marital status nor 
individual income, but family income was significantly 
higher among controls. As we can see at table 2, all do-
mains of quality of life are significantly impaired among 
PD patients under treatment, compared to controls.
Table 1. Sociodemographic data
Variable Panic disorder 
(n = 20)
Controls  
(n = 20)
p value
Gender
Male 7 (35%) 8 (40%) *0.74
Female 13 (65%) 12 (60%)
Age (years)
Mean (SD) 37.55 (9.06) 37.80 (10.28) *0.50  **0.99
18-29 4 (20%) 7 (35%)
30-39 7 (35%) 5 (25%)
40-49 8 (40%) 8 (40%)
> 49 1 (5%) 0 (0%)
Schooling 
(years)
Mean (SD) 12.10 (3.61) 11.95 (3.39) *0.69
4 – 8 2 (10%) 4 (20%)
9 – 11 10 (50%) 9 (45%)
> 11 8 (40%) 7 (35%)
Religion
Catholic 14 (70%) 15 (75%) *0.70
Evangelic 3 (15%) 2 (10%)
Not religious 2 (10%) 3 (15%)
Others 1 (5%) 0 (0%)
Marital status
Single 8 (40%) 7 (35%) *0.79
Married 9 (45%) 11 (55%)
Divorced or 
widowed
3 (15%) 2 (10%)
Individual 
income ($ US)***
Mean (SD) 416.08 (341.59) 681.68 (658.34) **0.22
Family Income  
($ US)***
Mean (SD) 807.16 (690.170) 1219 (1065.57) **0.049
* c2 test; ** Kruskal-Wallis test; ***  on 08.02.06 – 1 US$ = R$ 2,192.
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Table 2.  Quality of life domains
WHOQOL-BReF domains PD patients Mean (SD) Controls Mean (SD) p value
Physical 57.86 (17.56) 78.75 (10.71) *0.0001
Psychological 56.04 (18.31) 73.54 (10.32) *0.0012
Social 56.25 (25.92) 73.75 (16.94) *0.0147
Environmental 47.03 (16.92) 56.72 (12.96) *0.08  **0.049
* Kruskal-Wallis test; ** ANOVA test.
WHOQOL-BREF = World Health Organization – Quality of Life – brief version  (Fleck et al., 2000).
Most of the PD patients (65%) said they had physical 
illnesses. Three patients (15%) had systemic arterial 
hypertension, 15% related hypothyroidism, 10% referred 
dermatological illness, 10% had asthma, 10% headaches, 
5% gastritis and 5% hepatitis C. Although, all PD patients 
declared that those physical problems were under con-
trol, they were not presenting symptoms of them and 
were not bothered with those physical disea ses. Half of 
the patients had, at least, one psychiatric co-morbidity. 
Twenty-five percent had co-morbid major depression, 
generalized anxiety disorder was identified in 15% of PD 
patients, dysthymia in 10%, and 5% had social phobia. The 
mean age of onset of PD was 31 years old (SD = 8.278). 
At the moment the patients were assessed 10% were 
treating with tricycles antidepressants (TCA) as the only 
medicine, 20% were taking only SSRI, 40% were treating 
with TCA plus benzodiazepines (BZD), 10% SSRI plus 
BZD and 20% were on another regimen, including, for 
example, valproi c acid. Twenty percent were on cogni-
tive behavioral therapy, 15% were on psychoanalysis and 
65% had never done any kind of psychotherapy.
Analysis of the correlation of each of the four do-
mains of WHOQOL-BREF questionnaire with clinical 
features, anxiety measures, Axis IV and V results (from 
DSM-IV-TR) were shown on table 3 (analysis made with 
Kruskal-Wallis test). Smoking and higher state and trait 
anxiety measures were associated to physical quality 
of life impairment. Agoraphobia, higher BAI scores, 
lower global functioning scores and psychosocial pro-
blems (such as problems with intimate relationships, 
social environment, working problems and difficult to 
access health care services) were associated with worse 
psychological quality of life. Higher HARS scores, poorer 
global functioning and, as we expected, psychosocial 
problems (specially with intimate relationships, social 
environment, work, home, finances and access to health 
care services) were correlated with lower scores in the 
social quality of life domain. Environmental quality of 
life impairment is associated with smoking, lower global 
functioning assessment scores, higher state anxiety 
measures, environmental problems and also problems 
with finances and access to health care services.
Discussion
Information about quality of life may be used to estimate 
the impact of different disorders in the well being and 
global functioning of people21, and may also be used to 
evaluate different therapeutic modalities, outcome and 
response to treatment10.
The present study found that the diagnostic of PD 
is a factor significantly associated with worse scores in 
each of the four domains of quality of life evaluated by 
the WHOQOL-BREF questionnaire, when compared 
to controls. The significant difference in the family 
income between the two groups does not explain the 
worse scores of PD patients. The correlation between 
the family income and each quality of life domain did not 
detect significant association between them. No other 
demographical data was related to worse quality of life 
in our study, although, lower schooling and advanced 
age11 and also lower social class and being single22 were 
already described as factors related with poorer quality 
of life scores among PD patients. 
Our PD sample is composed by patients that are 
under treatment. Objective evaluation of PD patients 
by PAS analysis showed low (19) total scores of ± 13. 
None of the PD patients reported panic attacks in the last 
two weeks before the assessment. These data indicate 
that the severity of panic symptoms was under control 
even when self-report anxiety measures (BAI, STAI – 
Form Y) demonstrated that patients still generally felt, 
moderately to severely anxious. This may be secondary 
to antecipatory anxiety or agoraphobic symptoms. A 
cross-sectional study reported that PD patients presen-
ted worse quality of life scores than those with rare PA, 
and these had worse scores than controls23.
Recent literature indicates that higher severity of 
panic attacks and agoraphobia, prolonged PD course, 
major depression co-morbidity, problems in the primary 
care group, high interpersonal sensitivity, higher levels 
of neuroticism are some of the factors correlated with 
worse outcome among PD patients (11,22). Patients 
with severe agoraphobia have an unfavorable outcome 
of PD, with prolonged course, worse symptoms and ma-
jor social disability than patients with mild or no phobic 
symptoms24. Phobic avoidance leads to a poorer progno-
sis and quality of life impairment25,26. Agoraphobia may 
represent a more severe and morbid picture or a group 
of symptoms less responsive to treatment27. The greater 
disability associated with agoraphobia can lead PD to a 
chronic status. Most of the studies did not evaluate panic 
symptoms separately from agoraphobia27. Although, a 
recent study reported that PD patients in early phases 
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Table 3. Clinical and psychosocial features of panic disorder (PD) patients and correlation with quality of life domains
N (%) Physical 
domain  
(p value)
Psychological 
domain 
(p value)
Social 
domain 
(p value)
environmental 
domain 
(p value)
Smoking
Yes
No
In the past years
04 (20)
13 (65)
03 (15)
*0.02 0.49 0.18 *0.02
Medical comorbidities 13 (65) 0.07 0.09 0.09 0.09
Psychiatric comorbidities 10 (50) 0.36 0.18 0.42 0.17
Age of PD onset (years)
< 30
30-39
> 39
9 (45)
8 (40)
3 (15)
0.68 0.76 0.50 0.55
Agoraphobia 08 (40) 0.07 *0.03 0.15 0.09
STAI-S (Spielberger state anxiety)
Mean (SD)
High
Moderate
Low
43.50 (8.79)
01 (05)
16 (80)
03 (15)
*0.02 0.21 0.13 *0.02
STAI-T (Spielberger Trait Anxiety)
Mean (SD)
High
Moderate
Low
50.10 (9.19)
02 (10)
16 (80)
02 (10)
*0.04 0.25 0.19 0.06
BAI (Beck Anxiety Inventory)
Mean (SD)
Severe
Moderate
Mild
23.40 (15.0)
08 (40)
05 (25)
07 (35)
0.07 *0.03 0.13 0.16
HARS (Hamilton Anxiety Rating Scale)
Low
Moderate
Severe
8 (40)
8 (40)
4 (20)
0.66 0.10 *0.03 0.13
GAF (Global Functioning)
Mean (SD and T value)
Good
Moderate
Poor
66.95 (10.52 & 28.47)
11 (55)
07 (35)
02 (10)
0.18 *0.03 *0.02 *0.03
Primary Care Group 04 (20%) 0.13 *0.01 *0.01 0.10
Social environment 05 (25%) *0.05 *0.004 *0.02 *0.01
Occupational Problems 09 (45%) 0.94 *0.02 *0.01 0.22
Problems with the access to health care services 02 (10%) 0.10 *0.03 *0.02 *0.02
Home problems 06 (30%) 0.62 0.12 *0.04 0.06
Financial problems 13 (65%) 0.20 0.13 *0.02 *0.05
- p values were obtained performing the Kruskal-Wallis test
* p < 0.05 – significant
of the illness have poorer quality of life than healthy 
controls independently of co-morbid agoraphobia. PD 
patients with agoraphobia had lower quality of life scores 
at mental health domain, but not in physical domain, 
demonstrating that agoraphobia is important to poor 
mental health but not physical functioning28.
Quality of life among PD patients is at the same level 
as somatic diseases9,11. Nevertheless, chronic medical 
illness was not a risk factor for worse functioning in 
panic patients11. PD has negative effects in the physical 
and psychological functioning of patients compared to 
healthy controls. PD patients have worse psychological 
health than those with medical chronic disease29. The 
physical and psychological health levels of PD patients 
are comparable to those of depressed patients29. 
 Poor social support was one of the predictors of 
worse quality of life23. Problems in the primary care 
group are correlated with worse outcome among PD 
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patients22. In our study psychosocial problems such as: 
problems with intimate relationships, with social envi-
ronment, with access to health care services, problems 
with work and finances were related with psychological 
and social compromise.
The size of the sample is a limitation of our study as 
well as the absence of a control group of PD patients 
without treatment. In our analysis we did not specify the 
impact of co-morbid major depression alone and counted 
all psychiatric co-morbidities together. Another limita-
tion is the fact that our sample is formed by patients of 
a Research Center rather than a sample taken from the 
general population. But the present study is an important 
description, statistically significant, showing that PD 
diagnosis, even with PA under control, correlates with 
lower scores of quality of life.
Patients under treatment to PD presented worse quali-
ty of life scores, compared to healthy controls. High levels 
of anxiety (state and trait), psychosocial and environmental 
problems are also associated with quality of life impair-
ment. Agoraphobia is related specially with impairment 
on psychological quality of life domain. Demographic 
data did not correlate significantly to lower quality of life 
scores. In our sample the control of PA was not sufficient 
to improve quality of life among PD patients.
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